Botanical and Plant-Derived Drugs Markets, 2022

Dublin, Nov. 28, 2017 -- The "Botanical and Plant-Derived Drugs: Global Markets" report has been added to Research and Markets' offering.

The Global Market for Botanical and Plant-Derived Drugs will Grow from $29.4 Billion in 2017 to around $39.6 Billion by 2022 with a CAGR of 6.1%

Report Includes

• 27 tables
• An overview of the botanical drug industry, with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward
• Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
• A focus on legal, prescription-required therapeutic medicines sold in the open market; the study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall wellness rather than to address specific medical conditions or symptoms)
• Examination of the industry structure, competition, and market drivers
• Discussion of market size and segmentation, including breakdowns of sales by therapeutic area and geographic area
• Observations and conclusions regarding the future of the botanical and plant-derived drug industry

This report is an analytical business tool whose primary purpose is to describe the botanical drug industry with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward.

For the purposes of this report, botanicals are those drugs that are FDA-approved under the botanical drug pathway, while plant-derived drugs are both botanicals as well as other approved drugs that contain a mixture of natural plant-derived and synthetic or semisynthetic substances.

The study's main focus is on legal, prescription-required therapeutic medicines sold in the open market. The study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall wellness rather than to address a specific medical condition or symptoms). While there is a substantial market for these products, the medical value of many of these substances has not been demonstrated conclusively.

The Format Of The Study Is Organized Around The Following Topics:

• Major types and applications of botanical drugs with plant-derived drugs as their backdrop.
• Industry structure.
• Market size and segmentation, including the breakdown of sales by therapeutic area and geographic area.
• Market drivers.
• Market projections through 2022.
• Competition.
• Observations and conclusions regarding the future of the botanical and plant-derived drug industry.

Key Topics Covered:

1: Introduction

2: Summary and Highlights

• Trends and Drivers for Botanical Drug Development

3: Market and Technology Background

• Brief History of Plant-Derived Medicines
• Opportunity Lies Beyond What Is Known
• Getting Started
• Key Drivers
• Key Challenges
• U.S. Government Investment
• Industry Investment
• Nutrition Science Partners Ltd. (Nestle Health): A Case Study
• Botanical Drugs Defined
• Understanding the Regulatory Process
• Investigational New Drug Applications
• The First and Second U.S. Approved Botanical Drug
• Botanical Candidates in the Pipeline
• A Growing Pipeline
• Overall Pharma Landscape
• Major Classes of Plant Drugs
• Intellectual Property
• Production
• A New Type of Production: Plant-Made Drugs
• Drug Development and Manufacture

4: Market Breakdown by Technology Type

• Sales of Plant-derived Drugs by Region
• Plant-derived Drugs by Therapeutic Area
• Value of Plant-derived Drugs by Therapeutic Area
• A Pipeline Perspective: Composition of Botanical Drugs in Clinical Development

5: New Developments and Market Opportunities

• Hormone Therapy and Metabolism Applications
• Infectious Disease Applications
• Pain and Central Nervous System Disease Applications
• Cardiovascular and Metabolic Applications
• Respiratory, Inflammation (Both Nonrelated and Related to Orthopedic) and Autoimmune Applications
• Dermatology Applications
• Gastrointestinal Applications
• Oncology Applications
• Botanical Drugs in Clinical Development

6: Company Profiles

• Abbott Laboratories
• Artecef BV
• Bayer Healthcare Pharmaceuticals
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Cardax Pharmaceuticals
• Chi-Med
• Chong Kun Dang Pharmaceutical Corp.
• Eli Lilly
• Fytokem Products Inc.
• Galapagos Nv
• Glaxosmithkline
• Glenmark Pharmaceuticals Limited
• Heterogeneity Llc
• Hsrx Biopharmaceutical
• Indena
• Izun Pharmaceuticals Corp.
• Johnson & Johnson
• Lupin Pharmaceuticals Inc.
• Medigene Ag
• Merck & Co. Inc.
• Merlion Pharmaceuticals
• Microbio Co. Ltd.
• Mycosynthetix Inc.
• Napo Pharmaceuticals Inc.
• Novartis International AG
• Pfizer
• Pharmaceutical Plant Co.
• Phynova
• Sanofi
• Santalis Pharmaceuticals
• Schwabe Pharmaceuticals
• Sequoia Sciences Inc.
• Sun Pharmaceutical Industries Ltd.
• Yiviva

7: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/2w6xkn/botanical_and

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Pharmaceuticals